ACCEPTING APPLICATIONS · GRANT
DoW Rare Cancers Idea Development Award
Defense Health Agency Contracting Activity - DHACA · Science and Technology
- Deadline
- Nov 18, 2026 (24 days left)
- Who can apply
- Anyone eligible under the notice (unrestricted)
- Award range
- Not stated
- Expected awards
- 15
- Total program funding
- $7.3 million
- Your own money required
- No cost sharing or matching required
- Opportunity number
- HT942526RCRPIDA
- Posted
- Jun 17, 2026
- Assistance listing
- 12.420
What it funds
Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Idea Development Award (IDA) promotes ideas that are ready for further development and have the potential to yield high-impact findings and new avenues of investigation.Distinctive Features:The RCRP encourages applicants to include an exploratory aim or sub-aim to support any necessary discovery-driven research.Preliminary data with disease-specific rationale are required. However, these data do not necessarily need to originate from studies of the proposed rare cancer type(s)/subtype(s) under study.Research should have high potential impact on rare cancers and the patient community.
Open the official notice on Grants.gov ↗What to do next
- Open the official notice on Grants.gov and download the full announcement (the NOFO) and any attachments.
- Check you can apply: the eligible applicants above, and any detail in the notice's eligibility section.
- Register your organization in SAM.gov (choose "all awards") and create a Grants.gov account; allow several weeks the first time.
- Apply through Grants.gov exactly as the notice says, before Nov 18, 2026. Late applications are usually not accepted.
New to this? Applying for a federal grant, step by step · Register to apply · How to read the notice · Write the narrative · Build the budget · Agency contact: help@eBRAP.org
From Grants.gov's official daily extract of Oct 25, 2026. The notice on Grants.gov and its attachments are what count. UX Contract is independent and not a government website.